Immunomodulatory Effects of Endoscopic Ultrasound-Guided Thermal Ablation in Patients with Pancreatic Ductal Adenocarcinoma

Immunological consequences of endoscopic ultrasound (EUS)-local thermal ablation (LTA) for pancreatic ductal adenocarcinoma (PDAC) have not been extensively assessed. We aimed to explore EUS-LTA effects on the systemic immune response in PDAC. Peripheral blood was collected from 10 treatment-naïve patients with borderline resectable and locally advanced PDAC, randomly allocated to Nab-paclitaxel plus Gemcitabine chemotherapy (CT-arm, n = 5) or EUS-LTA with HybridTherm Probe plus CT (HTP + CT-arm, n = 5). Twenty healthy donors were included as controls. Flow-cytometry and multiplex assays were used to profile immune cell subsets and measure serum cytokines/chemokines, respectively. At baseline, PDAC patients showed increased circulating monocytes and lower circulating lymphocytes and CD19+ B cells counts compared to healthy controls. After 4 months, CT induced decrease of B regulatory cells, CD4+ cytotoxic T cells and IL-1β. The addition of EUS-HTP to CT selectively decreased the serum levels of APRIL/TNFSF13 as well as T regulatory cells, total, classic and inflammatory monocytes. Serum levels of APRIL/TNFSF13 and total, classic and inflammatory monocytes counts at baseline were associated with worse overall survival. EUS-HTP has the potential to selectively impact on immune cells and cytokines associated with poor outcomes in PDAC.

[1]  N. Thosani,et al.  Radiofrequency Ablation Remodels the Tumor Microenvironment and Promotes Neutrophil-Mediated Abscopal Immunomodulation in Pancreatic Cancer , 2022, Cancer immunology research.

[2]  B. Vincent,et al.  Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity , 2022, Cell reports. Medicine.

[3]  Song Gao,et al.  ESE3-positive PSCs drive pancreatic cancer fibrosis, chemoresistance and poor prognosis via tumour–stromal IL-1β/NF–κB/ESE3 signalling axis , 2022, British Journal of Cancer.

[4]  C. Lafon,et al.  Locoregional therapies and their effects on the tumoral microenvironment of pancreatic ductal adenocarcinoma , 2022, World journal of gastroenterology.

[5]  S. Testoni,et al.  B-Lymphocytes in the Pathophysiology of Pancreatic Adenocarcinoma , 2022, Frontiers in Immunology.

[6]  Qingqu Guo,et al.  Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review , 2021, Cell Communication and Signaling.

[7]  M. Reni,et al.  Efficacy of Endoscopic Ultrasound-Guided Ablation with the HybridTherm Probe in Locally Advanced or Borderline Resectable Pancreatic Cancer: A Phase II Randomized Controlled Trial , 2021, Cancers.

[8]  T. D. de Gruijl,et al.  Pancreatic Cancer and Immunotherapy: A Clinical Overview , 2021, Cancers.

[9]  F. Izzo,et al.  Local ablation of pancreatic tumors: State of the art and future perspectives , 2021, World journal of gastroenterology.

[10]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[11]  Yinting Chen,et al.  Peripheral blood monocytes predict clinical prognosis and support tumor invasiveness through NF-κB-dependent upregulation of Snail in pancreatic cancer , 2021, Translational cancer research.

[12]  L. You,et al.  Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides? , 2020, Frontiers in Oncology.

[13]  M. Reni,et al.  Necrosis volume and Choi criteria predict the response to endoscopic ultrasonography-guided HybridTherm ablation of locally advanced pancreatic cancer , 2020, Endoscopy International Open.

[14]  Ping Liu,et al.  Neoantigen-specific CD4+ T-cell response is critical for the therapeutic efficacy of cryo-thermal therapy , 2020, Journal for ImmunoTherapy of Cancer.

[15]  Yuanyuan Zhou,et al.  High-dimensional single-cell analysis delineates radiofrequency ablation induced immune microenvironmental remodeling in pancreatic cancer , 2020, Cell Death & Disease.

[16]  C. Dietrich,et al.  Systematic review of endoscopy ultrasound-guided thermal ablation treatment for pancreatic cancer , 2020, Endoscopic ultrasound.

[17]  M. Falconi,et al.  B lymphocytes contribute to stromal reaction in pancreatic ductal adenocarcinoma , 2020, Oncoimmunology.

[18]  Ping Liu,et al.  Tumor-related HSP70 released after cryo-thermal therapy targeted innate immune initiation in the antitumor immune response , 2020, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[19]  T. D. de Gruijl,et al.  Needle-guided ablation of locally advanced pancreatic cancer: cytoreduction or immunomodulation by in vivo vaccination? , 2019, Chinese clinical oncology.

[20]  elliot k fishman,et al.  Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies , 2019, Cancers.

[21]  E. Nakakura,et al.  NCCN GUIDELINES ® INSIGHTS CE Pancreatic Adenocarcinoma , Version 1 . 2019 Featured Updates to the NCCN Guidelines , 2019 .

[22]  I. Endo,et al.  Role of the tumor microenvironment in pancreatic cancer , 2019, Annals of gastroenterological surgery.

[23]  A. Gavin,et al.  Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. , 2018, European journal of cancer.

[24]  M. Falconi,et al.  Increase of circulating memory B cells after glucocorticoid-induced remission identifies patients at risk of IgG4-related disease relapse , 2018, Arthritis Research & Therapy.

[25]  T. Luedde,et al.  Differential Roles of Tumor Necrosis Factor Ligand Superfamily Members as Biomarkers in Pancreatic Cancer , 2018, Journal of Clinical Medicine.

[26]  J. Stone,et al.  A CD8α− Subset of CD4+SLAMF7+ Cytotoxic T Cells Is Expanded in Patients With IgG4‐Related Disease and Decreases Following Glucocorticoid Treatment , 2018, Arthritis & rheumatology.

[27]  R. Qin,et al.  Regulatory B cells induced by pancreatic cancer cell-derived interleukin-18 promote immune tolerance via the PD-1/PD-L1 pathway , 2017, Oncotarget.

[28]  Xianjun Yu,et al.  Circulating regulatory T cell subsets predict overall survival of patients with unresectable pancreatic cancer. , 2017, International Journal of Oncology.

[29]  Laurence Zitvogel,et al.  The immune contexture in cancer prognosis and treatment , 2017, Nature Reviews Clinical Oncology.

[30]  A. Javed,et al.  Overcoming the resistance of pancreatic cancer to immune checkpoint inhibitors , 2017, Journal of surgical oncology.

[31]  S. Curley,et al.  Pancreatic adenocarcinoma response to chemotherapy enhanced with non-invasive radio frequency evaluated via an integrated experimental/computational approach , 2017, Scientific Reports.

[32]  H. Takaki,et al.  Thermal ablation and immunomodulation: From preclinical experiments to clinical trials. , 2017, Diagnostic and interventional imaging.

[33]  L. Xu,et al.  The cryo-thermal therapy eradicated melanoma in mice by eliciting CD4+ T-cell-mediated antitumor memory immune response , 2017, Cell Death & Disease.

[34]  J. Long,et al.  The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients. , 2016, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[35]  Jefte M. Drijvers,et al.  Clonal expansion of CD4(+) cytotoxic T lymphocytes in patients with IgG4-related disease. , 2016, The Journal of allergy and clinical immunology.

[36]  T. Conroy,et al.  FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. , 2016, The Lancet. Oncology.

[37]  David Goldstein,et al.  Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. , 2016, JAMA.

[38]  C. Bassi,et al.  Local Ablative Strategies for Ductal Pancreatic Cancer (Radiofrequency Ablation, Irreversible Electroporation): A Review , 2016, Gastroenterology research and practice.

[39]  Hashim U. Ahmed,et al.  Harnessing the immunomodulatory effect of thermal and non-thermal ablative therapies for cancer treatment , 2015, Tumor Biology.

[40]  D. Dupuy,et al.  Thermal ablation of tumours: biological mechanisms and advances in therapy , 2014, Nature Reviews Cancer.

[41]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[42]  Jonathan B. Mitchem,et al.  Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis , 2013, Clinical Cancer Research.

[43]  M. Unno,et al.  Clinical features and treatment outcome of borderline resectable pancreatic head/body cancer: a multi-institutional survey by the Japanese Society of Pancreatic Surgery , 2013, Journal of hepato-biliary-pancreatic sciences.

[44]  M. Reni,et al.  Feasibility and safety of EUS-guided cryothermal ablation in patients with locally advanced pancreatic cancer. , 2012, Gastrointestinal endoscopy.

[45]  H. Toyokawa,et al.  Circulating CD4+CD25+ Regulatory T Cells in Patients With Pancreatic Cancer , 2012, Pancreas.

[46]  Yueguo Wang,et al.  Serum APRIL, a potential tumor marker in pancreatic cancer , 2011, Clinical chemistry and laboratory medicine.

[47]  Gang Li,et al.  Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. , 2011, Surgery.

[48]  I. Endo,et al.  FOXP3+ Regulatory T Cells and Tumoral Indoleamine 2,3-Dioxygenase Expression Predicts the Carcinogenesis of Intraductal Papillary Mucinous Neoplasms of the Pancreas , 2010, Pancreatology.

[49]  C. Doglioni,et al.  US-guided application of a new hybrid probe in human pancreatic adenocarcinoma: an ex vivo study. , 2010, Gastrointestinal endoscopy.

[50]  C. Doglioni,et al.  Endoscopic ultrasound-guided application of a new hybrid cryotherm probe in porcine pancreas: a preliminary study , 2008, Endoscopy.

[51]  Haesun Choi,et al.  Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  M. Mack,et al.  Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. , 2007, The Journal of clinical investigation.

[53]  Carl G. Figdor,et al.  In Situ Tumor Ablation Creates an Antigen Source for the Generation of Antitumor Immunity , 2004, Cancer Research.

[54]  H. Kalthoff,et al.  Systemic and local immunosuppression in pancreatic cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  K. Fearon,et al.  A polymorphism of the interleukin-1 β gene influences survival in pancreatic cancer , 2000, British Journal of Cancer.

[56]  Y. Mou,et al.  Role of Treg/Th17 Imbalance, Microbiota and miRNAs in Pancreatic Cancer: Therapeutic Options. , 2020, Critical reviews in immunology.

[57]  S. Hochwald,et al.  Ablative Therapies for Locally Advanced Pancreatic Cancer , 2018, Pancreas.